irbesartan

(redirected from Avalide)
Also found in: Medical.

ir·be·sar·tan

 (ĭr′bə-sär′tn)
n.
An angiotensin II receptor blocker drug, C25H28 N6O, used to treat hypertension.

[irbe-, origin unknown + -sartan, angiotensin II receptor blocker suff.; see losartan.]
Translations

irbesartan

n irbesartán m
References in periodicals archive ?
Blood pressure drugs Avapro and Avalide, which lost patent protection last March, dropped 57 percent to $84 million.
The resolution of these disputes includes various commitments by both companies, including a one-time payment of USD80m by Bristol-Myers Squibb to Sanofi in relation to the Avalide supply disruption in the US in 2011.
New York) is recalling 60 million tablets of the blood pressure medication Avalide in the United States and Puerto Rico.
The company has proposed that Avalide be indicated as initial treatment of severe hypertension.
In the pivotal trial, 47% of those on Avalide had achieved a diastolic blood pressure below 90 mm Hg at 5 weeks, the primary end point, compared with 33% of those on irbesartan monotherapy, a highly significant difference.
Combination drugs include Aldoril, Atacand HCT, Avalide, Benicar HCT, Diovan HCT, Dyazide, Hyzaar, Lotensin HCT, Maxzide, Micardis HCT.
609) 897-2072, and Sanofi Pharmaceuticals, (212) 551-4314, have introduced the companies' newest antihypertensive, Avalide (irbesartan/hydrochlorothiazide tablets), an angiotensin II receptor blocker (ARB) combined with a thiazide diuretic.
The resolution of these disputes includes various commitments by both companies, including a one-time payment of $80 million by Bristol- Myers Squibb to Sanofi in relation to the Avalide supply disruption in the U.
M2 EQUITYBITES-October 1, 2012-Mylan Inc unveils generic hypertension drugs Avapro & Avalide tablets(C)2012 M2 COMMUNICATIONS http://www.
M2 PHARMA-October 1, 2012-Mylan Inc unveils generic hypertension drugs Avapro & Avalide tablets(C)2012 M2 COMMUNICATIONS
The study was funded by the two companies that distribute Avalide in partnership, Bristol-Myers Squibb Co.
The resolution of these disputes includes various commitments by both companies, including a one-time payment of $80 million by Bristol-Myers Squibb to Sanofi in relation to the Avalide supply disruption in the U.